ClinicalTrials.gg
RecruitingNCT07399821GLOW-FISHUpdated Feb 10, 2026

An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma

A Phase 1/2 interventional study of anti-GD2-800CW in Neuroblastoma, sponsored by Princess Maxima Center for Pediatric Oncology. Recruiting at 1 site in Netherlands. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Princess Maxima Center for Pediatric Oncology · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Neuroblastoma with a site in Netherlands — 5 open to participants now, 6 under way, 1 of them phase 3. Neuroblastoma · Netherlands.

Planned enrollment
21st of 21
22 · median 115
Started
2025
with 1 other
Phase 1/2
4 of 23
2 open now
Registered
23rd of 23
by date
Lead sponsor
2 of 23
Princess Maxima Center for Pediatric Oncology

Among the 23 studies in Neuroblastoma with a site in Netherlands, this one is the 21st largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 in phase 1/2, and was the 23rd registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

5 of the 23 studies in Neuroblastoma with a site in Netherlands are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Neuroblastoma with a site in Netherlands, or all of them as a file.
02

Study summary

This is a non-randomized, open label phase Ib/II dose-escalation and expansion study designed to define the recommended dose of anti-GD2-800CW in pediatric neuroblastoma patients. The aim of this imaging study is to determine a safe and effective dose of anti-GD2-800CW for intra-operative detection of neuroblastoma using NIR fluorescence.

Read the detailed description

Neuroblastoma is the most commonly diagnosed extracranial solid tumor in young children. It is a neural crest derived malignancy, which are the cells that give rise to the sympathetic nervous system, and can therefore be located in different body compartments. However, it occurs most frequently (80%) in the abdomen. Current treatment involves debulking surgery using standard-of-care, not assisted by intra-operative visualization of the tumor. In this current situation there is, i) a high risk of severe complications such as bleeding or unplanned nephrectomy (40%), ii) a high chance of >10% residual tumor tissue, and iii) difficulty distinguishing neuroblastoma subtypes with varying malignancy. Therefore, there is a high need for new tools enabling tumor-specific intra-operative visualization to assist the surgeon. This will reduce surgical complications and ensure neuroblastoma cells can be visualized and resected during surgery. Over the past years, Fluorescence Guided Surgery (FGS) has proven to be a useful intraoperative tool to increase the visibility of the tumor in various adult cancers. Our group has developed and validated a tumor-specific fluorescent agent, anti-GD2-800CW, that can be used to visualize neuroblastoma during surgery. Anti-GD2-800CW consists of two substances. Firstly, the monoclonal antibody anti-GD2, also known as Qarziba or Dinutuximab-beta, which binds to Disialoganglioside 2 (GD2), a tumor-associated antigen specifically expressed by neuroblastoma, most melanomas and several other tumors. Immunotherapy with anti-GD2 is now standard therapy for high-risk neuroblastoma treatment in patients aged 12 months and above. Secondly, the near-infrared (NIR) fluorescent dye, IRDye800CW, which is used extensively in clinical trials as fluorescent imaging agent without any known adverse events (AEs). The aim of this study is to investigate the safety and efficacy of this novel agent, anti-GD2-800CW, to visualize neuroblastoma during surgery.

03

Conditions studied

  • Neuroblastoma

Browse trials for

Keywords

  • Neuroblastoma
  • Fluorescence Guided Surgery
  • NIR fluorescence
  • pediatric oncology
04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with the diagnosis of neuroblastoma as defined by histopathology (confirmed by the PMC Department of Pathology), who will be operated for NB as standard of care procedure
  • Patients older than 1 year of age and not older than 18 years.
  • Written from patients and/or from parents or legal guardians, according to local law and regulations

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with Dinutuximab-beta, either alone or in combination with chemotherapy
  • Pregnancy or positive pregnancy test (urine or serum) in females of . Pregnancy test must be performed within during the screening period and before the administration of the IMP.
  • Breast feeding.
  • Sexually active participants not willing to use highly effective method (pearl index \<1) as defined in CTFG HMA 2020 (Appendix I) during trial participation and until 6 months after end of protocol therapy.
  • Patients that received prior treatment with chimeric antibodies.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    anti-GD2-800CW

    Participants will receive a single dose of anti-GD2-800CW 96 hours prior to surgery.

    Drug: anti-GD2-800CW

Interventions

  • Druganti-GD2-800CW

    Participants will receive a single dose of anti-GD2-800CW 96 hours prior to surgery. In phase Ib, using a 3+3 design, a dose escalation is performed to determine the RP2D.

06

What researchers measure

Primary outcomes

  1. To establish the recommended phase 2 dose (RP2D), based on efficacy and safety, of the anti-GD2-800CW fluorescent imaging agent in pediatric patients with neuroblastoma.

    Establishing the recommended phase 2 dose (RP2D), based on efficacy and safety, of the anti-GD2-800CW fluorescent imaging agent.

    Time frame: Through escalation phase completion, an average of 1 year.

  2. To investigate safety of anti-GD2-800CW based on treatment related new AEs.

    Registration of new AEs.

    Time frame: From IMP administration to 4 days after surgery

Secondary outcomes

  1. To assess the pharmacodynamic characteristics of an i.v. injection of anti-GD2-800CW.

    Assessment will be done by measuring Anti Drug Antibody formation using an ADA binding assay. Blood samples will be taken at 8 time points.

    Time frame: From just before infusion to 4 days after surgery.

  2. To assess the pharmacokinetic characteristics of an i.v. injection of anti-GD2-800CW.

    Assessment will be done by by measuring plasma levels Dinutuximab. Dinutuximab levels will be measured over time to create a concentration-time profile per patient. Blood samples will be taken at 8 time points.

    Time frame: From just before infusion to 4 days after surgery.

  3. To correlate clinical imaging data with histopathology data to determine the accuracy for depicting GD-2 expressing vital tumor cells.

    Pathologic status of removed fluorescent tissue and of removed fluorescent tissue will be compared to fluorescent status.

    Time frame: From start surgery to 3 weeks after surgery when the PA results are analyzed.

  4. To assess the intra-operative usability of anti-GD2-800CW to distinguish tumor tissue from surrounding tissue on eyesight of the surgeons.

    Score of ≥ 4.0 on a Likert scale of 1-5 based on the judgement of three surgeons. They will grade the intra-operative visibility of the fluorescence and whether a clear distinction can be made on eyesight between tumor and surrounding tissue based on fluorescence.

    Time frame: From start surgery to 3 weeks after surgery when the PA results are analyzed.

  5. To assess whether tumor load influences the fluorescence intensity.

    Tumor load will be examined in preoperative imaging with the tumor volume (cm3). Additionally, we will denote the histopathological outcome with an estimation of vital tumor present after resection.

    Time frame: From pre-operative scan to when PA results are analyzed, 3 weeks after surgery.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Only IPD used in the results publication.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Apr 2027, 16 months after the start.

Of 35 phase 1/2 interventional studies under Neuroblastoma, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 62 and three quarters within 115. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Feb 10, 2026
StartActual
Nov 5, 2025
Primary completionEst.
Apr 1, 2027
CompletionEst.
May 1, 2027
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07399821
Lead sponsor
Princess Maxima Center for Pediatric Oncology
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Nov 5, 2025
Primary completion
Apr 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Feb 10, 2026

Study contacts

Marieke Kietselaer
Contact
trialmanagement@prinsesmaximacentrum.nl
+31 88 972 7272

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion